Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

1. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Lancet Oncol Actions . 2020 Mar;21(3):412-420. doi: 10.1016/S1470-2045(19)30827-7. Epub 2020 Jan 27. TAS-102 With or Without Bevacizumab in Patients With Chemorefractory Metastatic Colorectal Cancer: An Investigator-Initiated, Open-Label, Randomised, Phase 2 Trial , , , , , , , , , Affiliations Expand Affiliations 1 Department of Oncology, Odense University Hospital, Odense, Denmark; Department

2020 EvidenceUpdates

2. Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial

Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete (...) results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation JAMA Surg Actions . 2020 Jan 22;155(3):233-242. doi: 10.1001/jamasurg.2019.5474. Online ahead of print. Effect of Multimodal Prehabilitation vs Postoperative Rehabilitation on 30-Day Postoperative Complications for Frail Patients Undergoing Resection of Colorectal Cancer: A Randomized Clinical Trial

2020 EvidenceUpdates

3. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

adenomas 5 mm in size. Future studies may clarify whether length- ening the interval beyond 10 years may be possible. A 10- year follow-up after normal colonoscopy is recommended regardless of indication for the colonoscopy, except for in- dividuals at increased risk for CRC, such as those with his- tory of a hereditary CRC syndrome, personal history of in?ammatory bowel disease, personal history of hereditary cancer syndrome, serrated polyposis syndrome, malignant polyp, personal history of CRC (...) is in keeping with their values and preferences. This article does not include recommendations for follow-up for individuals with hereditary CRC syndromes (eg, Lynch syndrome and familial adenomatous polyposis), in?ammatory bowel disease, a personal history of CRC (includingmalignantpolyps),familyhistoryofCRCorcolo- rectal neoplasia, or serrated polyposis syndrome. As such, our recommendations for follow-up after colonoscopy and polypectomy do not apply to these groups except in cases where polyp ?ndings

2020 American Society for Gastrointestinal Endoscopy

4. Endoscopic Removal of Colorectal Lesions—Recommendations by the US Multi-Society Task Force on Colorectal Cancer

?brosis,local residual early carcinoma after endoscopic resection, and non-polypoid colorectal dysplasia in patients with in?ammatory bowel disease. 109 The technique of ESD involves an endoscopic knife for cuttingandsubmucosalinjectantforlifting.Aftersubmuco- sal injection, a circumferential incision is performed to isolate the lesion with 3 or 4 mm surrounding normal mu- cosa. The submucosa under the lesion is injected further. With controlled movements under direct view facilitated with the use (...) months to assess for local recurrence and to clear the colon of synchronous lesions. There is a very high prevalence of synchronous disease in patients with lesions 20 mm. In a large EMR referral cohort with lesions 20 mm, patients had an average of 4 additional conventional adenomas; 40% had an additional advanced adenoma; 20% had an additional lesion 20 mm; and 0.8% had a synchronous cancer not detected by the refer- ring physician. Of those referred for removal of a serrated lesion, 30% had

2020 American Society for Gastrointestinal Endoscopy

5. Regional Therapies for Colorectal Cancer Liver Metastases

Regional Therapies for Colorectal Cancer Liver Metastases Guideline 2-30a A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Regional Therapies for Colorectal Cancer Liver Metastases P. Karanicolas, R. Beecroft, R. Cosby, E. David, M. Kalyvas, E. Kennedy, G. Sapisochin, R. Wong, K. Zbuk and the Gastrointestinal Disease Site Group Report Date: March 10, 2020 For information about this document, please contact Dr. Paul Karanicolas or Dr. Robert (...) randomization to disease progression. Guideline 2-30a Section 3: Guideline Methods Overview - March 10, 2020 Page 9 Regional Therapies for Colorectal Cancer Liver Metastases Section 3: Guideline Methods Overview This section summarizes the methods used to create the guideline. For the systematic review, see Section 4. THE PROGRAM IN EVIDENCE-BASED CARE The PEBC is an initiative of the Ontario provincial cancer system, Ontario Health (Cancer Care Ontario) (OH [CCO]). The PEBC mandate is to improve the lives

2020 Cancer Care Ontario

6. Treatment of Patients with Late-Stage Colorectal Cancer Resource-Stratified Guideline Full Text available with Trip Pro

emergency colon or rectal cancer surgery. If resection is not possible, then patients should receive palliative care. , Palliative colostomy should be considered in situations of malignant bowel obstruction. In the assessment of general symptoms, clinicians should determine a patient’s performance status and comorbid conditions, as they can influence the ability to receive and predict the benefit from medical treatment. Diagnosis Recommendations on the methods of diagnosis for patients with colorectal (...) biomarker evaluation guideline. - TABLE 3 Recommendations on Symptom Management TABLE 4 Recommendations on Diagnosis TABLE 5 Recommendations on Staging Symptom Management Recommendations for assisting patients with symptoms of advanced colorectal cancer such as pain or bleeding are in . Discussion. More than 1.8 million patients in the world were diagnosed with colorectal cancer (CRC) in 2018. Among all patients with CRC, 20%-30% have metastatic disease from the outset (synchronous primary tumor

2020 American Society of Clinical Oncology Guidelines

7. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europ

because of palliative treatment and new biological treatments for advanced disease. BetterunderstandingofthenaturalhistoryofGIcancershas shown that most of them are preceded by slowly progressing precancerous conditions or lesions, as well as by early invasive stages, therefore providing opportunities for effective inter- ventions. Beyond the classic adenoma–carcinoma sequence for colorectal carcinogenesis, similar pathways based on metaplasia–dysplasia–cancer progression have been shown for upper GI (...) leadtounderuseorpoorresourcingofhealthfacilities involved inprovidingscreeningservices, with consequent failuretofully realizethe potential benefits to patients. Methods In 2017, the European Society of Gastrointestinal Endoscopy (ESGE) Governing Board established a task force (Public Affairs Working Group led by A.S.) to produce a Position Statement concerning the value of endoscopy for screening purposes in GI cancers. The most prevalent digestive cancers (esophageal squamous cellcarcinoma,esophagealadenocarcinoma,gastric carcinoma

2020 European Society of Gastrointestinal Endoscopy

8. Incidence of Incisional Hernia Repair After Laparoscopic Compared to Open Resection of Colonic Cancer: A Nationwide Analysis of 17,717 Patients (Abstract)

comprised of patients undergoing resection for colonic cancer between January 2007 and March 2016 according to the Danish Colorectal Cancer Group database. Patients who subsequently underwent IHR were identified in the Danish Ventral Hernia Database, from which information about the priority of the hernia repair and the size of the fascial defect was retrieved.The study included 17,717 patients, of whom 482 (2.7%) underwent subsequent IHR during a median follow-up of 4.7 (interquartile range 2.8-6.9 (...) Incidence of Incisional Hernia Repair After Laparoscopic Compared to Open Resection of Colonic Cancer: A Nationwide Analysis of 17,717 Patients It remains unknown whether laparoscopic compared to open surgery translates into fewer incisional hernia repairs (IHR). The objectives of the current study were to compare the long-term incidence of IHR and the size of repaired hernias between patients subjected to laparoscopic or open resection of colonic cancer.This was a nationwide cohort study

2020 EvidenceUpdates

9. Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectal cancer surgery Full Text available with Trip Pro

surgery for colorectal cancer were divided randomly into three groups: combined general-TAP anaesthesia (TAP group), combined general-thoracic epidural anaesthesia (TEA group) and standard general anaesthesia (GA group). The primary endpoint was duration of hospital stay. Secondary endpoints included gastrointestinal motility, pain scores and plasma levels of cytokines.In total, 180 patients were randomized and 165 completed the trial. The intention-to-treat analysis showed that duration of hospital (...) Randomized clinical trial of continuous transversus abdominis plane block, epidural or patient-controlled analgesia for patients undergoing laparoscopic colorectal cancer surgery The optimal analgesia regimen after laparoscopic colorectal cancer surgery is unclear. The aim of the study was to characterize the beneficial effects of continuous transversus abdominis plane (TAP) blocks initiated before operation on outcomes following laparoscopic colorectal cancer surgery.Patients undergoing

2020 EvidenceUpdates

10. Avapritinib (Ayvakit) - adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)

Avapritinib (Ayvakit) - adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) Drug Approval Package: AYVAKIT AYVAKIT " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: AYVAKIT Company: Blueprint Medicines Corporation Application Number: 212608 Approval Date: 01/09/2020 trong> Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF

2020 FDA - Drug Approval Package

11. Colorectal cancer

with early rectal cancer 23 Preoperative treatment for people with rectal cancer 24 Surgery for people with rectal cancer 26 Surgical technique for people with rectal cancer 27 People with locally advanced or recurrent rectal cancer 28 Surgical volumes for rectal cancer operations 29 Preoperative treatment for people with colon cancer 30 Duration of adjuvant chemotherapy for people with colorectal cancer 30 Colonic stents in acute large bowel obstruction 32 Molecular biomarkers to guide systemic anti (...) , and pT4 and/or pN2), performance status, any comorbidities, age and personal preferences. T o find out why the committee made the recommendation on duration of adjuvant chemotherapy for people with colorectal cancer and how it might affect practice, see rationale and impact. Colonic stents in acute large bowel obstruction Colonic stents in acute large bowel obstruction 1.3.15 Consider stenting for people presenting with acute left-sided large bowel obstruction who are to be treated with palliative

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

12. Dataset for histopathological reporting of gastrointestinal stromal tumours

infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013;73:3499–3510. 29. Brierley J, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017. CEff 090120 16 V3 Final Appendix A SNOMED coding Topography Tumour site SNOMED 2/3 code SNOMED CT terminology SNOMED CT code Oesophagus T-62000/T-56000 Entire oesophagus (body structure) 181245004 Stomach T-63000/T-57000 Entire stomach (body structure) 181246003 (...) allows formulation of a definitive management plan but also is used to: • provide accurate and complete data for cancer registration • provide feedback to other clinical specialties, including surgery, radiology and oncology • allow for high-quality clinical audit and research. GISTs are now considered the most common connective tissue tumour of the gastrointestinal (GI) tract. They have been the subject of great interest over the past decade as a much deeper understanding of the underlying molecular

2020 British Society of Gastroenterology

13. Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer

or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 4. 2 or 3 5. 1 and 4 6. colonography, computed tomographic/ or colonoscopy/ or endoscopy, gastrointestinal/ or sigmoidoscopy/ or ((occult blood.ti,ab. or occult blood/) and (feces/ or (faeces or fecal or faecal or colorectal).ti,ab.)) or (enema/ and barium sulfate/) 7. mammography/ or mammogra*.ti,ab. 8. (colonography or colonoscop* or fobt or sigmoidoscop*).ti,ab (...) or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).mp. 4. 2 or 3 5. 1 and 4 6. ((colonography or colonoscopy

2020 Community Preventive Services Task Force

14. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

; 51Introduction Colonoscopy is the key examination technique in colorectal cancer (CRC) screening programs for detection and treatment of early precursor lesions and timely diagnosis of colorectal cancer [1,2]. The quality of colonoscopy, which depends on both bowel preparation and examination technique, is the main determining factor that drives the protective effect of this invasive examination in decreasing the societal disease burden [3–5]. Over the last 15 years, several new techniques to improve polyp (...) in the surveillance of SPS patients. However, its routine use must bebalanced against practical considerations. Bisschops Raf et al. Advanced imaging for detection and differentiation of colorectal neoplasia: ESGE Guideline – Update 2019 … Endoscopy 2019; 51Detection and differentiation ofcolorectal neoplasia in inflammatory bowel disease (IBD) Patients with long-standing or extensive ulcerative colitis (UC) or Crohn’s disease are at an increased risk of developing CRC compared to the average risk population

2020 European Society of Gastrointestinal Endoscopy

15. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines Full Text available with Trip Pro

Sussex Hospitals NHS Foundation Trust, Chichester, UK. 6 Colorectal surgery, Raigmore Hospital, Inverness, UK. 7 Gastroenterology, Cardiff and Vale NHS Trust, Cardiff, UK. 8 Histopathology, Nottingham University Hospitals, Nottingham, UK. 9 Family History of Bowel Cancer Clinic, West Middlesex University Hospital, London, UK. 10 Imperial College, London, UK. 11 Histopathology, University College London, London, UK. 12 Centre for Medical Imaging, UCL, London, UK. 13 Endoscopy, St Marks Hospital (...) Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE). They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 years and over. They are the first guidelines that take into account the introduction of national bowel cancer screening. For the first time, they also

2020 EvidenceUpdates

16. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (35), 3401-3411 2019 Dec 10 FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109

2020 EvidenceUpdates

17. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clinical Cancer Res 2006; 12: 3389–3393 [80] Rodriguez-Bigas MA, Vasen HF, Lynch HT et al. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carci- noma. International Collaborative Group on HNPCC. Cancer 1998; 83: 240–244 [81] SchulmannK,BraschFE,KunstmannEetal.HNPCC-associatedsmall bowel cancer (...) cancer mortality in first- degree relatives ofearly-onset colorectal cancer cases. Dis Colon Rectum 2002; 45: 681–686 [107] Kune GA, Kune S, Watson LF. The role of heredity in the etiologyof large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989; 13: 124–129 ; discussion 9–31 [108] Samadder NJ, Smith KR, Hanson H et al. Increased riskofcolorectal canceramongfamilymembersofallages,regardlessofageofindex case at diagnosis. Clin Gastroenterol Hepatol 2015; 13: 2305–2311

2020 European Society of Gastrointestinal Endoscopy

18. Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with Gastrointestinal Cancer under Radiotherapy. Full Text available with Trip Pro

Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with Gastrointestinal Cancer under Radiotherapy. A huge amount of the efforts made by health teams is dedicated to caring for cancer patients. This study has aimed to investigate the effect of self-care training on life expectancy and quality of life (QOL) in patients with gastrointestinal cancer who were under radiotherapy.In this clinical trial, 50 patients were selected using the block (...) training improved the QOL and life expectancy of patients with gastrointestinal cancer who were under radiotherapy. Therefore, self-care training is recommended to improve the QOL and the life expectancy of cancer patients.

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

19. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Have inflammatory bowel disease Have hereditary syndromes that increase the risk of colorectal cancer, such as Lynch syndrome and familial adenomatous polyposis. Several factors influence individuals’ decisions whether to be screened, even when they are presented with the same information: Variation in an individual’s values and preferences A close balance of benefits versus harms and burdens (for example, for a baseline risk of 3%, FIT every two years results in five fewer deaths from colorectal (...) recommendations: an international comparison of high income countries . NHS. Bowel scope screening. . Navarro M , Nicolas A , Ferrandez A , Lanas A . Colorectal cancer population screening programs worldwide in 2016: An update . Levin TR , Corley DA , Jensen CD , et al . Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population . Cancer Research UK. Bowel cancer incidence statistics. . Danckert B FJ, Engholm G, Hansen HL, et al. NORDCAN: Cancer

2019 BMJ Rapid Recommendations

20. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register